Galecto, Inc. Logo

Galecto, Inc.

Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.

GLTO | US

Overview

Corporate Details

ISIN(s):
US36322Q1076
LEI:
Country:
United States of America
Address:
75 STATE STREET, 2109 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galecto, Inc. is a clinical-stage biotechnology company that pioneers novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its extensive research in galectin biology to develop galectin-3 modulators, targeting key pathways in fibrosis and cancer progression. Galecto has expanded its oncology pipeline to include dual ENL-YEATS and FLT3 inhibitors for treating specific genetic subsets of acute myeloid leukemia (AML). Its research focuses on critical disease drivers in various cancers, including melanoma and carcinomas, as well as severe fibrotic liver conditions. The company's mission is to develop highly efficacious and well-tolerated treatments to extend and improve the quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galecto, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galecto, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Galecto, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea 140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea 432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America MIST
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America MDXG
Mind Medicine (MindMed) Inc. Logo
Developing psychedelic-inspired medicines and novel therapies for brain health disorders.
United States of America MNMD
Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America MLYS
MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America MIRA

Talk to a Data Expert

Have a question? We'll get back to you promptly.